glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results in patients with overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical A randomized phase 2b trial
Description
Liu J, Pong A, Gallo S, Darekar A, Terra SG
November 2023: A report filed in the Journal of the American Medical Association found a link between taking Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) and an increased risk of adverse gastrointestinal events such as gastroparesis
In addition to its many effects on glucose metabolism, it also influences various physiologic processes, including the regulation of appetite, gastrointestinal motility, and cardiovascular benefits [1]
Qsymia (phentermine/topiramate) Approved - A combination medication that suppresses appetite and enhances feelings of fullness
[DOI] [PubMed] [Google Scholar] 391.Panjwani N., Mulvihill E.E., Longuet C., Yusta B., Campbell J.E., Brown T.J
Diabetol Metab Syndr 17 , 168 (2025)
